Medicus Pharma (MDCX) announced the company has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention in men with benign prostatic hyperplasia as part of its existing open investigational new drug for Teverelix.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Sharpens SkinJect Phase 2 Narrative, Pivots to 200µg Dose for Registrational Path
- Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate
- Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2
- Medicus Pharma reports principal investigator validation of Phase 2 data
- Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan